|
|
Bristol-Myers Squibb Co.
|
 |
||||||||
|
 |
  |
 |
|
|
||
 |
 |
 
|
return to message board, top of board |
Re: Monitoring the developing Multiple Myeloma (MM) chessboard CELG first articulated in May2018A KOL involved in Iberdomide and CC-92480 trials is Dr Sagar Lonial and here are his thoughts. Indeed it’s like chessboard moves whilst navigating through Revlimid patent expiration. Given the recent developments (drug pricing reforms initiatives by government) i think BMY will have no option but to accelerate wherever possible their development plans and let iberdomide and CC-92480 cannibalize Revlimid revenues soonest. Easier said than done. |
||||||||||||
|
|
return to message board, top of board |
| Msg # | Subject | Author | Recs | Date Posted |
| 10146 | Re: Monitoring the developing Multiple Myeloma (MM) chessboard CELG first articulated in May2018 | grafzeppelin | 10 | 8/15/2022 7:51:52 AM |
